Vaxess Technologies

Executive Summary

Vaxess Technologies (operating as Terrestrial) is a Cambridge-based biotechnology company developing a novel microarray patch (MAP) platform for pain-free, self-administered delivery of vaccines and therapeutics. Its dissolvable microneedle patches aim to improve patient compliance, eliminate cold-chain storage, and enable at-home administration. The company is initially focused on vaccine delivery but is expanding into next-generation therapies such as GLP-1 agonists for metabolic diseases. Vaxess’s platform has the potential to address key challenges in global immunization and chronic disease management by offering a needle-free, temperature-stable alternative. With a strong intellectual property portfolio and early partnerships, the company is positioning itself as a leader in transdermal drug delivery. However, it remains in a development stage with no approved products, and its success hinges on clinical validation and manufacturing scale-up.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 trial initiation for GLP-1 agonist microneedle patch45% success
• Q3 2026Announcement of strategic partnership with major pharma for vaccine MAP60% success
• Q2 2026Series C funding round or government grant for manufacturing scale-up70% success